Evidence‑Based Guidance on Vyvanse and Azstarys for ADHD

Mechanism of Action

Both amphetamine‑based (Vyvanse) and methylphenidate‑based (Azstarys) stimulants inhibit reuptake of dopamine and norepinephrine, but amphetamines additionally promote neurotransmitter release from presynaptic terminals, whereas methylphenidate exhibits agonist activity at serotonin 1A receptors. [National Comprehensive Cancer Network, 2010] [1]
Amphetamines further inhibit vesicular monoamine transporter 2 (VMAT2) and monoamine oxidase activity, mechanisms not shared by methylphenidate. [Pharmacology and Therapeutics, 2022] [2]

Vyvanse (lisdexamfetamine) is enzymatically hydrolyzed in red blood cells to active d‑amphetamine, providing a once‑daily, full‑day therapeutic effect. [Pediatrics, 2011] [3]
Azstarys delivers 30 % immediate‑release dexmethylphenidate and 70 % delayed release from its serdexmethylphenidate prodrug, achieving symptom control from approximately 0.5 h to 13 h post‑dose in laboratory classroom studies. [No citation – omitted]

Both Vyvanse and Azstarys are FDA‑approved first‑line stimulant options for children, adolescents, and adults with ADHD. [Pharmacology and Therapeutics, 2022] [4]
If an initial methylphenidate trial fails, lisdexamfetamine (Vyvanse) is recommended as the next stimulant choice before considering non‑stimulant agents. [Pharmacology and Therapeutics, 2022] [4]
Approximately 70 % of pediatric patients respond to methylphenidate monotherapy, and more than 90 % respond when both methylphenidate and amphetamine classes are sequentially tried. [Pediatrics, 2000; Pediatrics, 2019] [6] 7

Routine monitoring of blood pressure and heart rate is required for all patients receiving either stimulant, with avoidance in individuals who have uncontrolled hypertension, coronary artery disease, or tachyarrhythmias. [National Comprehensive Cancer Network, 2010] [1] 8
Common early‑treatment adverse effects include decreased appetite, insomnia, and irritability; clinicians should assess these symptoms within the first few days of therapy. [National Comprehensive Cancer Network, 2010] [1] 8

Vyvanse’s prodrug design reduces abuse potential relative to immediate‑release amphetamines; it must be metabolized in red blood cells before becoming active, making extraction difficult. [Pediatrics, 2011] [3]
Real‑world data indicate that oral misuse of Vyvanse is approximately 75 % lower than that of immediate‑release dextroamphetamine, although pharmacodynamic effects remain comparable when taken orally. [No citation – omitted]
Azstarys, as a methylphenidate‑based prodrug, exhibits lower abuse potential compared with cocaine‑type stimulants. [National Comprehensive Cancer Network, 2010] [1]

Initial selection between a methylphenidate‑based stimulant (Azstarys) and an amphetamine‑based stimulant (Vyvanse) should be guided by patient/family preference, comorbid conditions, and required duration of coverage. [Pharmacology and Therapeutics, 2022] [4]
If the first stimulant fails, switching to the alternative class yields a response in nearly 90 % of patients. [Journal of the American Academy of Child and Adolescent Psychiatry, 2002] [10]
Dose titration should be performed over several weeks using standardized parent and teacher rating scales, with regular assessment of side effects, blood pressure, pulse, height, and weight. [Journal of the American Academy of Child and Adolescent Psychiatry, 2002] [10]

All facts are presented in English, with patient identifiers generalized to maintain privacy.